[go: up one dir, main page]

PE20020062A1 - 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a - Google Patents

5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a

Info

Publication number
PE20020062A1
PE20020062A1 PE2001000475A PE2001000475A PE20020062A1 PE 20020062 A1 PE20020062 A1 PE 20020062A1 PE 2001000475 A PE2001000475 A PE 2001000475A PE 2001000475 A PE2001000475 A PE 2001000475A PE 20020062 A1 PE20020062 A1 PE 20020062A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
halogen
triazolo
pyrazolo
Prior art date
Application number
PE2001000475A
Other languages
English (en)
Inventor
Craig D Boyle
Samuel Chackalamannil
William J Greenlee
Yan Xia
Bernard R Neustadt
Lisa S Silverman
Deen Tulshian
Neil Lindo
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20020062A1 publication Critical patent/PE20020062A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA DE FORMULA I DONDE R ES R1-FURANILO, R1-TIENILO, R1-PIRIDILO, ENTRE OTROS; X ES ALQUILENO, COCH2; Y ES NR2CH2CH2NR3, OCH2CH2NR2, O, S, CH2S, (CH2)2NH, GRUPO a; m Y n SON 2-3; Q ES N, CH, COH, ENTRE OTROS; Z ES R5-FENILO, R5-FENILALQUILO, R5-HETEROARILO, DIFENILMETILO, GRUPO b, R6CO, ENTRE OTROS; Z E Y SON PIPERIDINILO, FENILO, GRUPO c; R1 ES H, ALQUILO C1-C6, CF3, HALOGENO, NO2; R2, Y R3 SON H, ALQUILO C1-C6; R4 ES H, ALQUILO C1-C6; R5 ES H, HALOGENO, ALQUILO C1-C6, OH, ALCOXI C1-C6, ENTRE OTROS; R6 ES ALQUILO C1-C6, R5-FENILO, TIENILO, ENTRE OTROS; R7 ES ALQUILO C1-C6, R5-FENILO, ENTRE OTROS; R8 ES H, ALQUILO C1-C6 O R7 Y R8 SON (CH2)p-A-(CH2)q; p Y q SON 2-3; A ES UN ENLACE, CH2, S, O; R9 ES H, ALQUILO C1-C6, OH, ALCOXI C1-C6, HALOGENO, ENTRE OTROS; R10 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R11 ES H, ALQUILO C1-C6, FENILO, ENTRE OTROS; R12 ES H, ALQUILO C1-C6; R13 ES ALQUILO C1-C6-CO, ALQUILO C1-C6-SO2. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON ANTAGONISTAS DE RECEPTORES DE ADENOSINA A2a Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DEPRESION, ENFERMEDADES COGNITIVAS, ENFERMEDADES NEURODEGENERATIVAS, APOPLEJIA, PARKINSON
PE2001000475A 2000-05-26 2001-05-24 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a PE20020062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20714300P 2000-05-26 2000-05-26

Publications (1)

Publication Number Publication Date
PE20020062A1 true PE20020062A1 (es) 2002-02-02

Family

ID=22769372

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000475A PE20020062A1 (es) 2000-05-26 2001-05-24 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a

Country Status (31)

Country Link
US (4) US6630475B2 (es)
EP (1) EP1283839B1 (es)
JP (3) JP4574112B2 (es)
KR (1) KR100520907B1 (es)
CN (2) CN1247588C (es)
AR (1) AR028621A1 (es)
AT (1) ATE293627T1 (es)
AU (2) AU6808901A (es)
BR (1) BRPI0111015B8 (es)
CA (1) CA2410237C (es)
CZ (1) CZ303790B6 (es)
DE (1) DE60110219T2 (es)
DK (1) DK1283839T3 (es)
EC (1) ECSP024364A (es)
ES (1) ES2237576T3 (es)
HK (1) HK1049007B (es)
HU (1) HU230420B1 (es)
IL (3) IL152726A0 (es)
MX (1) MXPA02011625A (es)
MY (1) MY132006A (es)
NO (1) NO325008B1 (es)
NZ (1) NZ522326A (es)
PE (1) PE20020062A1 (es)
PL (1) PL218764B1 (es)
PT (1) PT1283839E (es)
RU (1) RU2315053C2 (es)
SI (1) SI1283839T1 (es)
SK (1) SK287748B6 (es)
TW (1) TWI288137B (es)
WO (1) WO2001092264A1 (es)
ZA (1) ZA200208898B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6808901A (en) * 2000-05-26 2001-12-11 Schering Corp Adenosine a2a receptor antagonists
JP2005516891A (ja) * 2001-09-13 2005-06-09 シェーリング　コーポレイション アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
IL160878A0 (en) 2001-10-15 2004-08-31 Schering Corp Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
MXPA04005209A (es) * 2001-11-30 2004-08-19 Schering Corp Antagonistas del receptor de adenosina a2a.
MXPA04005158A (es) 2001-11-30 2004-08-11 Schering Corp Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol.
CN101822676A (zh) 2002-01-28 2010-09-08 协和发酵麒麟株式会社 治疗运动疾病患者的方法
EP1549319A2 (en) 2002-05-30 2005-07-06 King Pharmaceuticals Research and Development Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP2269596A3 (en) * 2002-12-19 2011-09-14 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
US20070010522A1 (en) 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
PE20050141A1 (es) 2003-04-23 2005-04-01 Schering Corp DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
US8202869B2 (en) * 2003-06-10 2012-06-19 Kyowa Hakko Kirin Co., Ltd. Method of treating an anxiety disorder
JP2006527212A (ja) * 2003-06-12 2006-11-30 ノボ　ノルディスク　アクティーゼルスカブ ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
WO2005044819A1 (en) 2003-10-28 2005-05-19 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
CA2547248A1 (en) * 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
AU2004303425C1 (en) * 2003-12-19 2010-02-18 Schering Corporation Pharmaceutical compositions
TW200538118A (en) 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
EP2258372B8 (en) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
ATE538123T1 (de) * 2005-09-19 2012-01-15 Schering Corp 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
PE20070521A1 (es) * 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
US8669260B2 (en) * 2008-02-29 2014-03-11 Albert Einstein College Of Medicine Of Yeshiva University Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
EP2262811B1 (en) 2008-03-04 2016-04-27 Merck Sharp & Dohme Corp. 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
EP2274007B1 (en) 2008-03-10 2016-12-14 Cornell University Modulation of blood brain barrier permeability
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
BRPI0916203A2 (pt) 2008-07-23 2018-05-15 Kyowa Hakko Kirin Co Ltd agente terapêutico e/ou preventivo para enxaqueca, método para tratar e/ou prevenir enxaqueca, e, uso de um composto
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
MX2011007678A (es) 2009-01-20 2011-08-08 Schering Corp Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa.
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
US8537177B2 (en) * 2009-06-15 2013-09-17 Marvell World Trade Ltd. System and methods for gamut bounded saturation adaptive color enhancement
EP2462144B1 (en) 2009-08-07 2017-09-20 Merck Sharp & Dohme Corp. PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106105A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
JP5868948B2 (ja) 2010-04-19 2016-02-24 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的脱メチル化酵素１阻害薬およびその使用
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP3375775A1 (en) 2010-07-29 2018-09-19 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
CN103261202B (zh) * 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012129381A1 (en) * 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
WO2013024474A1 (en) * 2011-08-18 2013-02-21 Mapi Phrarma Ltd. Polymorphs of preladenant
IL264982B (en) 2011-10-20 2022-08-01 Oryzon Genomics Sa Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
WO2014071512A1 (en) * 2012-11-06 2014-05-15 Universite Laval Combination therapy and methods for the treatment of respiratory diseases
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
RU2727805C2 (ru) 2014-11-18 2020-07-24 Мерк Шарп И Доум Корп. Аминопиразиновые соединения со свойствами антагониста a2a
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
WO2016200717A1 (en) 2015-06-11 2016-12-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
WO2018178338A1 (en) * 2017-03-30 2018-10-04 Iteos Therapeutics 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CN115873022A (zh) * 2017-03-30 2023-03-31 伊忒欧斯比利时股份公司 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
SG11202006435XA (en) 2018-01-04 2020-08-28 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CN108276345A (zh) * 2018-03-22 2018-07-13 重庆奥舍生物化工有限公司 一种药物中间体嘧啶-5-甲醛的制备方法
EA202092036A1 (ru) 2018-04-08 2021-01-28 Бейджин, Лтд. Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
SG11202106582YA (en) 2018-12-20 2021-07-29 Incyte Corp Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12325708B2 (en) 2019-05-03 2025-06-10 Nektar Therapeutics Adenosine 2 receptor antagonists
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
JP2022540583A (ja) * 2019-07-17 2022-09-16 テオン セラピューティクス，インク． アデノシンａ２ａ受容体アンタゴニスト及びその使用
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法
CN112500416B (zh) 2019-07-30 2021-12-17 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类化合物中间体的制备方法
CN111072675A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法
CN118812544A (zh) * 2024-06-19 2024-10-22 厦门大学 一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物
CN118812539B (zh) * 2024-06-19 2025-11-28 苏州大学 一种5-氨基三唑并嘧啶衍生物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
SU1739850A3 (ru) * 1987-08-31 1992-06-07 Такеда Кемикал Индастриз, Лтд (Фирма) Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) * 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU6808901A (en) * 2000-05-26 2001-12-11 Schering Corp Adenosine a2a receptor antagonists
MXPA04005209A (es) * 2001-11-30 2004-08-19 Schering Corp Antagonistas del receptor de adenosina a2a.
EP2269596A3 (en) * 2002-12-19 2011-09-14 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
WO2005044819A1 (en) * 2003-10-28 2005-05-19 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
CA2547248A1 (en) * 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
TW200538118A (en) * 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
ATE538123T1 (de) * 2005-09-19 2012-01-15 Schering Corp 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors

Also Published As

Publication number Publication date
SK16712002A3 (sk) 2003-08-05
NZ522326A (en) 2006-03-31
BRPI0111015B1 (pt) 2017-11-07
JP2007145875A (ja) 2007-06-14
US7067655B2 (en) 2006-06-27
CZ303790B6 (cs) 2013-05-09
DE60110219D1 (de) 2005-05-25
CZ20023886A3 (cs) 2003-02-12
EP1283839B1 (en) 2005-04-20
ES2237576T3 (es) 2005-08-01
IL152726A0 (en) 2003-06-24
ECSP024364A (es) 2003-03-31
ZA200208898B (en) 2004-03-01
US20050026932A1 (en) 2005-02-03
NO20025651D0 (no) 2002-11-25
MXPA02011625A (es) 2003-03-27
US20040023997A1 (en) 2004-02-05
CN1247588C (zh) 2006-03-29
CN1800186A (zh) 2006-07-12
JP2003535094A (ja) 2003-11-25
BRPI0111015B8 (pt) 2021-05-25
JP4574112B2 (ja) 2010-11-04
JP4938348B2 (ja) 2012-05-23
ATE293627T1 (de) 2005-05-15
KR100520907B1 (ko) 2005-10-11
KR20030003746A (ko) 2003-01-10
EP1283839A1 (en) 2003-02-19
US20020099061A1 (en) 2002-07-25
RU2315053C2 (ru) 2008-01-20
PL360472A1 (en) 2004-09-06
IL220174A0 (en) 2012-07-31
US6897216B2 (en) 2005-05-24
HUP0600239A3 (en) 2008-06-30
HK1049007A1 (en) 2003-04-25
CN100384847C (zh) 2008-04-30
PL218764B1 (pl) 2015-01-30
TWI288137B (en) 2007-10-11
AU2001268089B2 (en) 2005-04-28
HU230420B1 (hu) 2016-05-30
AR028621A1 (es) 2003-05-14
MY132006A (en) 2007-09-28
USRE44205E1 (en) 2013-05-07
HK1049007B (en) 2005-09-16
SI1283839T1 (es) 2005-08-31
CN1451007A (zh) 2003-10-22
AU2001268089C1 (en) 2006-04-13
NO325008B1 (no) 2008-01-14
IL220174A (en) 2015-07-30
NO20025651L (no) 2003-01-23
JP2006219497A (ja) 2006-08-24
WO2001092264A1 (en) 2001-12-06
CA2410237A1 (en) 2001-12-06
SK287748B6 (sk) 2011-08-04
IL152726A (en) 2012-07-31
AU6808901A (en) 2001-12-11
BR0111015A (pt) 2005-01-11
DE60110219T2 (de) 2006-03-09
US6630475B2 (en) 2003-10-07
DK1283839T3 (da) 2005-07-25
HUP0600239A2 (en) 2006-07-28
PT1283839E (pt) 2005-08-31
CA2410237C (en) 2008-01-08

Similar Documents

Publication Publication Date Title
PE20020062A1 (es) 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a
PE20030477A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
CO5700778A2 (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20030739A1 (es) Antagonistas del receptor de adenosina a2a
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
PE20081192A1 (es) Tratamiento del dolor
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20030129A1 (es) Imidazotriazinas
PE46899A1 (es) Derivados de n-fenil-sulfonamida
PE20010964A1 (es) Derivados de tiazolilamida
PE20040197A1 (es) Pirazolopiridinas sustituidas con carbamato
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
AR072756A2 (es) Intermediarios para la preparacion; derivados de triazolo[4,5-d]pirimidina, utiles como antitromboticos
PE20020406A1 (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS
PE20030727A1 (es) 17OALQUIL-17ß-OXI-ESTRATRIENOS, PRODUCTOS INTERMEDIARIOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR035068A1 (es) Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
AR065863A1 (es) Derivados de imidazolidinona
PE109598A1 (es) Pirrolcarboxamidas condensadas, utiles como ligandos de receptores cerebrales gaba
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20030653A1 (es) COMPUESTOS BICICLICOS[1,2,4]-TRIAZOL COMO ANTAGONISTAS DE RECEPTORES DE ADENOSINA A2a

Legal Events

Date Code Title Description
FG Grant, registration